Evidence map›Paper›PMID 41158492›Full record

ReviewERJ open research2025

Screening and monitoring across the lifespan of an ageing cystic fibrosis population.

Karin Yaacoby-Bianu, Raya Cohen, Michal Shteinberg

Abstract readReview
In one paragraph

Review in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karin Yaacoby-BianuPediatric Pulmonology Unit and CF Center, Carmel Medical Center, Haifa, Israel.
Raya CohenPulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel.
Michal ShteinbergB. Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.ORCID https://orcid.org/0000-0002-0432-3398

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) is a genetic disorder with involvement of many organ systems. For some of the affected organs, the dysfunction is a direct consequence of cystic fibrosis transmembrane conductance regulator (CFTR) deficiency, while in others the pathophysiology is complex and may be influenced by treatments and social factors. Recent decades have seen improved wellbeing and survival of people with CF, even more so with the introduction of CFTR modulator treatments. For many manifestations of CF, the focus has shifted from treatment of complications to screening and monitoring for early detection of complications, and prevention of treatment-related complications. Examples are early detection of

Identifiers

PMID41158492
PMCPMC12557414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.